Revlimid gets OK in Europe for some patients with MDS

06/17/2013 | MDSBeacon.com

The European Medicines Agency has approved the use of Celgene's Revlimid, or lenalidomide, in some myelodysplastic syndromes patients. The approval covers the use of the drug in patients with low- or intermediate-1-risk myelodysplastic syndrome and deletion 5q chromosomal abnormalities but no other chromo­somal ab­nor­mali­ties and who have become dependent on red blood cell transfusions and are not responding to other treatments.

View Full Article in:

MDSBeacon.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC